)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Chugai Pharmaceutical
Chugai Pharmaceutical (4519) investor relations material
Chugai Pharmaceutical Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary27 Oct, 2026
Executive summary
9M FY2026 core revenue was ¥1,068.1bn (+17.2% YoY); IFRS operating profit was ¥522.6bn (+21.6%) and core operating profit was ¥536.1bn (+19.0%).
Growth reflected higher sales and other revenue, including royalties and one-time income; domestic wholesaler shipments were also brought forward into Q3.
Results were tracking ahead of full-year targets, with management expecting to exceed the forecast.
Financial highlights
Sales were ¥906.8bn (+14.1% YoY); other revenue was ¥161.3bn (+37.7%), supported by Hemlibra and NEMLUVIO royalties and one-time income.
Core net income was ¥384.7bn (+20.2%); IFRS net income was ¥375.3bn (+22.8%).
Cost of sales rose 19.4% to ¥314.3bn; the cost-to-sales ratio increased 1.6 points to 34.7%, reflecting product mix.
Core R&D expense rose 9.6% to ¥141.2bn; SG&A increased 10.8% to ¥76.9bn, including higher enterprise tax and temporary expenses.
Outlook and guidance
FY2026 guidance remains unchanged: revenue ¥1,345bn, core operating profit ¥670bn, core net income ¥485bn and core EPS ¥295.
Nine-month progress was 79.4% for revenue, 80.0% for operating profit, 79.3% for net income and 79.2% for EPS; sales progress was 82.4%.
Hemlibra sales were expected near forecast; Actemra was expected to exceed its ¥130.8bn forecast by more than ¥10bn, and exports to Roche were expected to exceed forecast.
FY2026 dividend forecast was ¥132 per share, with a core dividend payout ratio of 44.7%.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Chugai Pharmaceutical
- Double-digit revenue and profit growth in H1 FY 2026, led by strong sales and pipeline progress.4519
Q2 2026 - Strong Q1 growth in revenue and profit, led by Hemlibra and NEMLUVIO exports and new launches.4519Q1 2026
- Record revenue and profit in 2025, with strong 2026 outlook and high shareholder returns.4519Q4 2025
- ESG leadership, innovation, and governance drive sustainable value and growth.4519Investor Update
- Strong revenue and profit growth, pipeline advances, and a special dividend highlight the period.4519Q3 2025
- Revenue and profit rose on robust sales, R&D progress, and a special 100th Anniversary dividend.4519Q2 2025
- Record profit and net income driven by Hemlibra and Actemra exports despite lower revenue.4519Q2 2024
- Strong overseas sales and pipeline advances drive robust Q1 growth and special dividend.4519Q1 2025
- Record 2024 results and special dividend highlight robust global growth and strong 2025 outlook.4519Q4 2024
Next Chugai Pharmaceutical earnings date
Q4 202628 Jan, 2027
Chugai Pharmaceutical
Next Chugai Pharmaceutical earnings date
Q4 202628 Jan, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Chugai Pharmaceutical Co., Ltd., operating under the umbrella of F. Hoffmann-La Roche Ltd, is a notable player in the pharmaceutical industry, mainly in Japan. Chugai is dedicated to the research, development, commercialization, and manufacture of biopharmaceuticals and therapeutic antibodies. The company's product range focuses on several therapeutic areas such as cancer, bone and joint diseases, renal diseases, and immune disorders, among others. It also plays a significant role in the global healthcare market through its international operations in North America, Europe, and other regions in Asia. Chugai Pharmaceutical is headquartered in Tokyo, Japan, and its shares are listed on the Tokyo Stock Exchange.